Recent evidence has shown that GLP1‐RAs, compared with other antidiabetic medications, are associated with a statistically significant decreased risk for pancreatic cancer, with incidence hazard ratios ranging from 0.42 to 0.82; the reduction was greater in patients with obesity [11, 64, 65]. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.